Novel tetrahydroisoquinolines as DHFR and CDK2 inhibitors: synthesis, characterization, anticancer activity and antioxidant properties

被引:5
|
作者
Sayed, Eman M. [1 ]
Bakhite, Etify A. [2 ]
Hassanien, Reda [1 ]
Farhan, Nasser [1 ]
Aly, Hanan F. [3 ]
Morsy, Salma G. [4 ]
Hassan, Nivin A. [5 ]
机构
[1] New Valley Univ, Fac Sci, Dept Chem, El Kharja 72511, Egypt
[2] Assiut Univ, Fac Sci, Dept Chem, Assiut 71516, Egypt
[3] Natl Res Ctr, Dept Therapeut Chem, El Behooth St, Cairo 12622, Egypt
[4] Assiut Univ, South Egypt Canc Inst, Dept Canc Biol, Canc Immunol & Virol Unit, Assiut, Egypt
[5] Assiut Univ, South Egypt Canc Inst, Dept Canc Biol, Pharmacol & Expt Oncol Unit, Assiut, Egypt
关键词
Anticancers; Apoptosis; Cell cycle arrest; CDK2; inhibitor; DHFR inhibitor; Antioxidants; Tetrahydroisoquinolines; Tetrahydrothieno[2,3-c]isoquinolines; CYCLIN-DEPENDENT KINASES; BIOLOGICAL EVALUATION; ISOQUINOLINE; DERIVATIVES; PROLIFERATION;
D O I
10.1186/s13065-024-01139-w
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
In this study, we synthesized new 5,6,7,8-tetrahydroisoquinolines and 6,7,8,9-tetrahydrothieno[2,3-c]isoquinolines based on 4-(N,N-dimethylamino)phenyl moiety as expected anticancer and/or antioxidant agents. The structure of all synthesized compounds were confirmed by spectral date (FT-IR, 1H NMR, 13C NMR) and elemental analysis. We evaluated the anticancer activity of these compounds toward two cell lines: A459 cell line (lung cancer cells) and MCF7 cell line (breast cancer cells). All tested compounds showed moderate to strong anti-cancer activity towards the two cell lines. Compound 7e exhibited the most potent cytotoxic activity against A549 cell line (IC50: 0.155 mu M) while compound 8d showed the most potent one against MCF7 cell line (IC50: 0.170 mu M) in comparison with doxorubicin. In addition, we examined the effect of compounds 7e and 8d regarding the growth of A549 and MCF7 cell lines, employing flow cytometry and Annexin V-FITC apoptotic assay. Our results showed that compound 7e caused cell cycle arrest at the G2/M phase with a 79-fold increase in apoptosis of A459 cell line. Moreover, compound 8d caused cell cycle arrest at the S phase with a 69-fold increase in apoptosis of MCF7 cell line. Furthermore, we studied the activity of these compounds as enzyme inhibitors against several enzymes. Our findings by docking and experimental studies that compound 7e is a potent CDK2 inhibitor with IC50 of 0.149 mu M, compared to the Roscovitine control drug with IC50 of 0.380 mu M. We also found that compound 8d is a significant DHFR inhibitor with an IC50 of 0.199 mu M, compared to Methotrexate control drug with IC50 of 0.131 mu M. Evaluation of the antioxidant properties of ten compounds was also studied in comparison with Vitamin C. Compounds 1, 3, 6, 7c and 8e have higher antioxidant activity than Vitamin C which mean that these compounds can used as potent antioxidant drugs.
引用
收藏
页数:19
相关论文
共 50 条
  • [31] Advances in synthesis and biological evaluation of CDK2 inhibitors for cancer therapy
    Patel, Dharmesh A.
    Patel, Siddharth S.
    Patel, Hitesh D.
    BIOORGANIC CHEMISTRY, 2024, 143
  • [32] Endogenous angiotensin II induces insensitivity of CDK2 activity to CDK2 inhibitors in vascular smooth muscle cells from SHR
    Ikeda, Y
    Fukuda, N
    Kubo, A
    Suzuki, R
    Tahira, Y
    Takagi, H
    Kishioka, H
    Kanmatsuse, K
    JOURNAL OF HYPERTENSION, 2002, 20 : S30 - S30
  • [33] Pyrazole ring-containing isolongifolanone derivatives as potential CDK2 inhibitors: Evaluation of anticancer activity and investigation of action mechanism
    Wang, Yunyun
    Shi, Wei
    Wu, Chenliang
    Wan, Lin
    Zhao, Yuxun
    Zhang, Chenglong
    Gu, Wen
    Wang, Shifa
    BIOMEDICINE & PHARMACOTHERAPY, 2021, 139
  • [34] Molecular Modeling and Design Studies of Purine Derivatives as Novel CDK2 Inhibitors
    Zhang, Gaomin
    Ren, Yujie
    MOLECULES, 2018, 23 (11):
  • [35] Fusion of Structure and Ligand Based Methods for Identification of Novel CDK2 Inhibitors
    Mahajan, Priya
    Chashoo, Gousia
    Gupta, Monika
    Kumar, Amit
    Singh, Parvinder Pal
    Nargotra, Amit
    JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2017, 57 (08) : 1957 - 1969
  • [36] DESIGN, SYNTHESIS AND BIOLOGICAL ESTIMATION OF INNOVATIVE PYRAZOLES AS ANTICANCER AGENTS TARGETING CDK2
    Radini, Ibrahim Ali M.
    Ibrahim, Diaa A.
    Khidre, Rizk E.
    ACTA POLONIAE PHARMACEUTICA, 2019, 76 (03): : 453 - 468
  • [37] Novel Azine Linked Hybrids of 2-Indolinone and Thiazolodinone Scaffolds as CDK2 Inhibitors with Potential Anticancer Activity: In Silico Design, Synthesis, Biological, Molecular Dynamics and Binding Free Energy Studies
    Qayed, Wesam S.
    Hassan, Mostafa A.
    El-Sayed, Wael M.
    Silva, Jose Rogerio A.
    Aboul-Fadl, Tarek
    BIOORGANIC CHEMISTRY, 2022, 126
  • [38] Novel approaches to CDK2 modulation: Hit identification, characterization, and optimization
    Deng, Yongqi
    Shipps, Gerald W.
    Curran, Patrick J.
    Zhao, Lianyun
    Siddiqui, Arshad
    Popovici-Muller, Janeta
    Duca, Jose S.
    Hruza, Alan W.
    Fischmann, Thierry O.
    Madison, Vincent S.
    Zhang, Rumin
    McNemar, Charles W.
    Mayhood, Todd W.
    Lees, Emma M.
    Parry, David A.
    Windsor, William T.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2010, 240
  • [39] DESIGN, SYNTHESIS AND CHARACTERIZATION OF NOVEL SERIES OF 1,3-THIAZOLE CONTAINING HETEROCYCLES AS INHIBITORS OF DHFR FOR USE AS ANTICANCER AGENTS
    Pawar, Sunil Dilip
    Mithila, N. S.
    Yadav, Abhishek
    Bhat, Shraddha
    Varghese, Roshni
    Sharma, Anjali
    Somayaji, Sharvari
    Sanjukta, G. P.
    Vibha, S.
    Agarwal, Anil Kumar
    CONFERENCE ON DRUG DESIGN AND DISCOVERY TECHNOLOGIES, 2020, 355 : 99 - 102
  • [40] Development of 9H-purine scaffold as novel CDK2 inhibitors: Design, synthesis, and biological evaluation
    Zhang, Yan
    Liu, Xiya
    Li, Ziming
    Wang, Xia
    Tang, Chunlei
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2025, 122